MOMENTUS Perspective
-
Industry leader Ed Shifflett, PhD joins MOMENTUS as Chief Growth Officer & Managing Partner
MOMENTUS BioPharma Consulting Group announced today that Ed Shifflett, PhD has joined the company as Chief Growth Officer and Managing Partner. John “Zeke” Czekanski, CEO, shared “The growth and trajectory of the company support Ed joining us as Chief Growth Officer and a full partner. Clients have responded extremely well to our forward-thinking strategies driven…
-
-
The MOMENTUS Approach to Readiness: Navigating the New Era of BioPharma Transformation
Biopharma leaders regularly tell us that the pace and magnitude of transformation are raising the bar for every decision. Data, speed, and advanced analytics are redefining how therapies are developed, accessed, and delivered, placing greater emphasis on value and, ultimately, better patient outcomes. Forward-thinking, cost-effective, nimble strategies that accelerate the approval and adoption of life-changing…
-
-
MFN Monitor: Europe’s Drug Launch Model Is Becoming a U.S. Pricing Risk
Traditional Global Launch Strategies Are Now Under Pressure For decades, the commercial path for innovative therapeutics followed a relatively predictable pathway. Secure FDA-approval, establish strategic pricing and a robust commercial footprint in US, and expand into Europe shortly thereafter. That framework has now come under attack due to the uncertainty related to the pricing policy…
-
-
FDA Raises the Evidence Bar for Rare Disease Biotechs: Jan 2025 to Apr 2026 Analysis
Key Takeaways An FDA In Chaos, But the Dust May Be Settling Starting mid 2025, a great deal of biopharma media attention has centered on FDA rejections of rare disease medicines as the administration’s new leaders have replaced the once predictable, career scientist-driven agency. Vinay Prasad announced his plan to depart the Center for Biologics…
-
-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues,…
-
-
J.P. Morgan Healthcare Conference, the “Superbowl of Healthcare” – 2026 Watchlist
In December 2025, as we prepare for JP Morgan Healthcare on Jan 12-15, 2026, the U S Congress will be refining federal government funding of US Healthcare as influenced by the One Big Beautiful Bill Act (OBBBA). Spending on Medicare Part D drugs and overall Medicaid programs are once again in the cross hairs, and…
-
-
Convergence of US FDA & Drug Pricing
The FDA, under new leadership, is taking an unprecedented role in drug pricing by linking approval incentives—like Priority Vouchers—to economic impact and Most Favored Nation (MFN) pricing. This blurs the traditional separation between regulatory review and payer negotiation, pressuring prices from day one. These shifts could reshape biopharma valuations, launch strategies, and access dynamics. Companies…
-
-
Industry Leaders Scott Roberts and John “Zeke” Czekanski Launch MOMENTUS Biopharma Consulting
LANTANA, Fla., Nov. 5, 2025 /PRNewswire/ — Industry leaders Scott Roberts and John “Zeke” Czekanski announced today they have partnered to form MOMENTUS Biopharma Consulting, LLC (“MOMENTUS” or “the Company”), a purpose-built strategic consulting group. Headquartered in Lantana, FL with an additional location in Boston, MA, MOMENTUS offers integrated strategic solutions across the therapeutic life cycle, sharpening the focus on value…
-
